Search

Your search keyword '"Openshaw, Peter Jm"' showing total 112 results

Search Constraints

Start Over You searched for: Author "Openshaw, Peter Jm" Remove constraint Author: "Openshaw, Peter Jm"
112 results on '"Openshaw, Peter Jm"'

Search Results

2. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

3. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

4. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

5. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : development and validation of the 4C Mortality Score

6. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol : prospective observational cohort study

7. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

8. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

9. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

10. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

11. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

12. Differentiation of COVID-19 from other emergency infectious disease presentations using whole blood transcriptomics then rapid qPCR: a case-control and observational cohort study

13. Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID)

15. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

16. SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study

17. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses

18. Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study

20. Circulating histones play a central role in COVID-19-associated coagulopathy and mortality

21. Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses

22. Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol

23. SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection

24. Procalcitonin is not a reliable biomarker of bacterial co-infection in people with COVID-19 undergoing microbiological investigation at the time of hospital admission

25. Admission blood glucose level and its association with cardiovascular and renal complications in patients hospitalised with COVID-19:glucose, cardiovascular outcomes and COVID-19

26. Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus

27. Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus

28. Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study

29. Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19

30. Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

31. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

32. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses

33. Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors : a cross-sectional study

34. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

35. Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19

36. Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK

37. Plasma steroid profiles in patients hospitalised with COVID-19 - an ISARIC/WHO CCP-UK cohort study

38. Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study

39. Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave

41. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study

42. Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study

43. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study

44. Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study

45. Bronchiolitis

46. Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study

47. Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19

48. Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19

49. A haemagglutination test for rapid detection of antibodies to SARS-CoV-2

50. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score

Catalog

Books, media, physical & digital resources